Generic placeholder image

Current Medical Imaging


ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Research Article

The Combination of FDG PET/CT and Contrast Enhanced CT in the Evaluation of Recurrent Pancreatic Carcinoma and Cholangiocarcinoma

Author(s): Steven Peti, Reza Fardanesh, Sivan Golan, William Simpson, Christopher Chin, Sasan Roayaie, Myron Schwartz, Daniel Labow and Lale Kostakoglu

Volume 10, Issue 1, 2014

Page: [53 - 61] Pages: 9

DOI: 10.2174/1573405609666131112193016

Price: $65


Objectives: The aim of our study was to evaluate the incremental value of of 18F-flouro-2-deoxyglucose (FDG) positron emission tomography (PET) performed with non-contrast enhanced computed tomography (non-ceCT) to the contrast enhanced CT (ceCT), and the advantage of combined evaluation over either modality alone in the detection of recurrent pancreatic carcinoma and cholangiocarcinoma.

Methods: A retrospective analysis was done on 47 patients with a history of pancreatic carcinoma (n=24) or cholangiocarcinoma (n=23), all of whom were referred for restaging with a FDG-PET/non-ceCT and a ceCT study during the follow- up period after first-line therapy. Histological and radiological follow-up were used to determine the accuracy of the imaging findings.

Results: A lesion-based analysis showed, when equivocal lesions were considered negative, that the sensitivity and specificity of PET/ceCT were 89.1% and 76.9% , respectively, whereas those of PET/non-ceCT were 71.4% and 80.8% , respectively, and those of ceCT were 63.9% and 84.6% , respectively. PET/ceCT had significantly higher sensitivity compared to PET/non-ceCT (p =0.0003) and ceCT alone (p=0.0003). When equivocal lesions were considered positive, the sensitivity and specificity of PET/ceCT were 93.3% and 69.2% , respectively, whereas those of PET/non-ceCT were 77.3% and 80.8% , respectively, and those of ceCT were 76.5% and 55.1% , respectively. Within the PET/ceCT group, negative reading increased specificity from 69.2% to 76.9% (p= 0.04), at no significant cost to sensitivity (decrease from 93.3% to 89.1% , p= 0.07).

Conclusions: PET/non-enhanced CT when interpreted together with ceCT, significantly improves sensitivity of restaging of pancreatic and cholangiocarcinomas at a minor expense to specificity. Our results provide evidence that ceCT and PET/CT are complementary tests that enhance the diagnostic accuracy of restaging in patients with pancreatic and cholangiocarcinomas.

Keywords: Pancreatic carcinoma, cholangiocarcinoma, recurrence, positron emission tomography, computed tomography.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy